rejected a Gilead Sciences Inc patent application related to its costly
hepatitis C drug, a U.S. advocacy group said, adding the move may lead
to other countries to consider rejecting patents for the controversial
Gilead has drawn
fire for the cost of its top-selling drug Sovaldi, priced at $1,000 per
pill in the United States or $84,000 for a typical 12-week course and
its patents have been challenged in the U.S., India and Europe.
application China has rejected was for a so-called prodrug, the
inactive form of the drug which then converts into the chemically active
compound once in the body, the New York-based Initiative for Medicines,
Access & Knowledge (I-MAK) said.
Labels: China, patent, Sovaldi